IL6 and COVID-19: With the growing application of immune-targeted therapies, agents such as the IL-6 inhibitor (tocilizumab), which has shown potential benefit in managing delirium among critically ill COVID-19 patients (49), may warrant future investigation in AID populations for both prevention and treatment.